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In-vitro activity of chlorhexidine, hexetidine and
bacitracin against perinatal pathogens
J Anthnicrob Chemother 1996; 37: 192-194
Sir,
To prevent microbial contamination and 
subsequent infection of the newborn during 
birth, it ’would be desirable to have a safe and 
efficacious antimicrobial agent that could be 
applied to the vaginal mucosa to prevent trans­
mission of neonatal pathogens during labour. 
We studied the in-vitro activities of three 
possibly useful agents: chlorhexidine, hexe­
tidine and bacitracin against clinical isolates of 
Chlamydia trachomatis (5 strains), Ureaplasma 
urealyticum (4), Mycoplasma hominis (4), 
Streptococcus agalactiae (50), Escherichia coli 
(50) and Listeria monocytogenes (10). Refer­
ence strains were C. trachomatis ATCC 
VR348B, U. urealyticum ATCC 27618 and 
ATCC 27813, M. hominis ATCC 14027 
and ATCC 23114, S. agalactiae ATCC 13813 
and NTCC 8181, E . coli ATCC 25922 and 
Staphylococcus aureus ATCC 29213,
Susceptibility testing of S. agalactiae,
E , coli, L. monocytogenes and S> aureus was 
performed by broth dilution in microtitre 
plates according to the guidelines of the 
NCCLS. Bacteria were grown on blood agar 
overnight at 37°C. Serial dilutions of the three 
test drugs were prepared in Iso-sensitest broth 
(Oxoid CM 473, Basingstoke, UK) in microt­
itre plates containing final concentrations of 
0.25-1024 mg/L of chlorhexidine, 4-256 mg/L 
of hexetidine and 1.0-8192 mg/L of bacitracin 
per well; 100 /zL of each dilution were mixed 
with an equal volume containing 104cfu of 
each bacterial strain in broth. Plates were 
incubated for 18 h at 37°C and the MIC was 
read as the lowest concentration of each drug 
completely inhibiting growth.
Strains of M. hominis were grown in 65.5 mL 
PPLO broth (Difco 0554, Detroit, USA) 
supplemented with 10 mL yeast extract, 10 mL 
horse serum, 10 mL L-arginine hydrochloride,
1.5 mL thallium acetate, 0.002% w/v phenol 
red and lOOOIU/mL penicillin (final pH 7.0). 
Strains of U. urealyticum were cultured in 
90 mL 3% w/v Trypticase Soy broth (Oxoid 
CM 129, Basingstoke, UK) supplemented with
3.6 mL yeast extract, 24 mL inactivated horse 
serum, 3 mL 40% w/v urea, 0.002% w/v 
phenol red, 40 mg/L cefuroxime and 4 mg/L 
amphotericin B (final pH 6.0). A suspension 
of 20,000 colour changing units/mL was 
mixed with 1 mL of each dilution of each drug, 
incubated for 30 min at 37°C and diluted 
100-fold in broth medium. One mL was then
pipetted into four culture tubes which were 
incubated for 72 h at 37°C. The MIC was read 
as the lowest concentration of each drug to 
inhibit growth in all four tubes.
Strains of C. trachomatis were grown on 
McCoy cells in flat bottom tubes as described by 
Heessen & Muytjens (1984). Growth medium 
consisted of Eagle’s MEM with HEPES 20mM,
3 % inactivated fetal bovine serum, 6 g/L glucose, 
50 mg/L gentamicin, 100 mg/L vancomycin,
2.5 mg/L fungizone and 1 mg/L cycloheximide. 
After inoculation, centrifugation (60 min at 
3000 rpm) and incubation (72 h at 37°C), 
cultures were homogenized, fixed with 
methanol and stained with monoclonal anti­
bodies for demonstration of inclusion bodies 
by immunofluorescence. A suspension of
20,000 inclusion forming units/mL was mixed 
with 1 mL of each dilution of test drug, left for 
30 min, diluted 100-fold in chlamydia growth 
medium and 1 mL was inoculated on to each of 
four culture tubes and screened for inclusions 
after 72 h at 37°C. The MIC was defined as the 
lowest concentration of each drug completely 
inhibiting formation of inclusions.
The results of the in-vitro tests are given 
in the Table. Hexetidine did not inhibit
C. trachomatis and E. coli, but was highly 
active against the other organisms; bacitracin 
only inhibited Gram-positive organisms; all 
strains were susceptible to 512 mg/L chlorhex­
idine or less. Although hexetidine was found to 
reduce the vaginal microflora by preoperative 
application (Wewalka et aL> 1991, Weidinger 
et al., 1991), we think that it would be 
unsuitable for perinatal antisepsis, it not being 
active against E. coli and C. trachomatis which 
are significant neonatal pathogens. The same 
conclusion was made for bacitracin. For 
chlorhexidine we calculated that 10 mL of 1% 
chlorhexidine solution would result in local 
concentrations of 0.4 mg/cm2 assuming the 
surface area of the normal vagina during 
labour being about 250 cm2. This concen­
tration is far above the highest MIC for the 
organisms tested, being the volumetric MIC of 
512 mg/L equivalent to 0.064 mg/cm2. This is 
in agreement with the experience that chlorhex­
idine can indeed prevent neonatal transmission 
of S. agalactiae (Kollee et al., 1989; Burman 
et aL> 1992). Chlorhexidine has been used in 
obstetrics and gynaecology for several pur­
poses and is not absorbed to any large extent 
(Vorherr et al., 1984), making it a safe 
substance. It may be of interest to study the 
efficacy of routine vaginal application of 
chlorhexidine in the prevention of several 
neonatal infections.
Table. In-vitro activities o f  chlorhexidine and hexetidine against C. trachomatis, U. urealyticum, M. hominis, 5 . agalactiae, £ .  co/i, and L. monocytogenes and of bacitracin
against 5 . agalactiae and monocytogenes
Antimicrobial agent and organism (no. tested) Cumulative number of organisms susceptible to concentrations (mg/L) indicated
Chlorhexidine 0.25 0.5 1 2 4 8 16 32 64 128 256 512
C. trachomatis (6) I 4a 6
U . urealyticum (6) 6“
M . hominis (6) 6a
S . agalactiae (52) 1 43 51° 52*
E . coli (51) 20® 50 51
L . monocytogenes ( 10) 4 10
S. aureus ATCC 29213 1
Hexetidine 4 8 16 32 64 128 256
C. trachomatis (6) 0
U. urealyticum (6) 6a
M . hominis (6) 6a
S. agalactiae (52) 12 52*
E . coli (51) 0
L. monocytogenes (10) 10
S. aureus ATCC 29213 1
Bacitracin 1 2 4 8 16 32 64 128 256
S. agalactiae (52) 3a 4 7 18 31 48 51 52°
L. monocytogenes (10) 5 10
S. aureus ATCC 29213 1
^Indicates MIC o f  reference strain.
i—i
UJ
C
orrespondence
194 Correspondence
Acknowledgements, We thank M. Gielen, 
J. Kissing and H, G. R. Roelofs-Willemse for 
technical assistance and Dr J. P, Donnelly for 
reviewing the manuscript. This work was 
supported in part by a grant from Zeneca, 
Ridderkerk, The Netherlands.
A. H. ADRIAANSE“,
H. L. MUYTJENSb,
F, W. A. FIEESSENb, 
J. M. D. GALAMAb 
J, A. A. HOOGKAMP-KORSTANJEb
aDepartment o f Obstetrics and Gynaecology; 
bDepartment o f  Medical Microbiology, 
University Hospital Nijmegen St Radboud,
PO Box 9101, 6500 HB Nijmegen,
The Netherlands
Telephone; +31-20 5669111. Fax: +31-20 6963489.
References
Burnian, L. G,, Christensen, P., Christensen, K., 
Fryklund, B., Helgesson, A. M., Svenningsen, N. 
W. et al. (1992). Prevention of excess neonatal 
morbidity associated with group B streptococci by 
vaginal chlorhexidine disinfection during labour. 
Lancet 340, 65-9.
Heessen, F. W, A. & Muytjens, H. L. (1984). In vitro 
activities of ciprofloxacin, norfloxacin, pipemidic 
acid, cinoxacin, and nalidixic acid against 
Chlamydia trachomatis. Antimicrobial Agents and 
Chemotherapy 25, 123-4.
Kollee, L. A. A., Speyer, I., van Kuijck, M. A. P., 
Koopman, R., Dony, J, M., Bakker, J. H. el al. 
(1989). Prevention of group B streptococci 
transmission during delivery by vaginal appli­
cation of chlorhexidine gel. European Journal of  
Obstetrics, Gynecology, and Reproductive Biology
31, 47-51,
Vorherr, H., Vorherr, U. F., Mehta, P., Ulrich, J. A. 
& Messer, R. H. (1984). Antimicrobial effect of  
chlorhexidine and povidone-iodine on vaginal 
bacteria. Journal o f  Infection 8, 195-9.
Weidinger, H., Passloer, H. J., Kovacs, L. & Berle,
B. (1991). Advantage of prophylactic vaginal 
antisepsis by hexetidine in obstetrics and gynecol­
ogy. Geburtshilfe und Frauenheilkunde 51, 929-35.
Wewalka, G., Dorninger, G., Enzelsberger, H., Riel, 
T. & Rotter, M, (1991). Antimicrobial efficacy of  
procedures for preoperative vaginal antisepsis. 
Hygiene mul Medizin 16, 335-45.
Paradoxical susceptibility to cephalofhin and
cefamandole of a Klebsiella pneumoniae isolate 
producing ext ende d-spect rum /Mactamase
(TEM-3).
J Antimicrob Chemother 1996; 37: 194-196
Sir,
Extended-spectrum ß-lactamases (ESBL) are
plasmid-mediated enzymes which confer resist­
ance to most /Mactam antibiotics, including 
first-generation cephalosporins and oxyimino- 
/Mactams such as cefotaxime, ceftazidime and 
aztreonam. Since their discovery in the mid 
1980s, about 40 enzymes have been identified, 
most of them derived by one or more amino 
acid substitutions from TEM or SHV enzymes. 
Most ESBL are inhibited by clavulanic acid, 
tazobactam or sulbactam, and can be readily 
detected by the double-disc synergy test 
showing that ^-lactam activity is restored by 
the addition of clavulanic acid (Philippon, 
Arlet & Lagrange, 1994). Klebsiella pneumoniae 
is the most common bacterial species in 
which clavulanate-sensitive ESBL have been 
identified, and outbreaks of hospital-acquired 
infections involving multiresistant strains of 
this organism have been reported (Philippon 
et a l 1994).
During a survey of intestinal carriage of 
K. pneumoniae resistant to third-generation 
cephalosporins in patients hospitalized in a 
surgical intensive care unit (Hôpital Boucicaut, 
Paris), a strain (BOU 92) producing an 
unusual ESBL was isolated from a patient by 
cultivating stools on Drigalski agar containing 
2 mg/L cefotaxime. Surprisingly, this isolate, 
although resistant to amoxycillin, ticarcillin, 
piperacillin, cefotaxime, ceftazidime and 
aztreonam, was susceptible to cephalothin and 
cefamandole (Table). In addition, strain BOU 
92) was resistant to aminoglycosides (except 
for gentamicin), trimethoprim, sulphonamides, 
tetracycline, fosfomycin and quinolones. 
Resistance to /Mactams was transferred by 
conjugation from K. pneumoniae strain BOU 
92 to Escherichia coli K-12 recipient strain 
HB101 and the recombinant strain was 
designated MS 92.1. Unlike the Klebsiella 
donor strain, the E. coli transconjugant was 
resistant to cephalothin and cefamandole 
(Table). Resistance to -lactams was then 
transferred by conjugation from the E . coli 
transconjugant MS 92.1 to a wild-type strain of 
K, pneumoniae (JLG III. 10) and the K. 
pneumoniae transconjugant (strain MS 92,2) 
exhibited the same phenotype as the E. coli 
donor strain (Table).
BOU 92, MS 92.1 and MS 92.2 all produced 
an identical plasmid-mediated /Mactamase 
with pi of 6.3 as determined by isoelectric 
focusing on polyacrylamide gel of crude cell 
sonic extracts with TEM-1 and TEM-3 
enzymes as pi markers (Jarlier et aL, 1988). 
The /Mactam resistance pattern and the 
enzyme pi strongly suggested that the ESBL 
produced was TEM-3; this assumption was 
confirmed by gene amplification with primers
